Search

The rotational spectrum of 2-furonitrile (2-cyanofuran) has been obtained from 140 to 750 GHz, capturing its most intense rotational transitions at ambient temperature. 2-Furonitrile is one of two isomeric cyano-substituted furan derivatives, both of which possess a substantial dipole moment due to the cyano group. The large dipole of 2-furonitrile allowed over 10 000 rotational transitions of its ground vibrational state to be observed and least-squares fit to partial octic, A- and S-reduced Hamiltonians with low statistical uncertainty (σfit= 40 kHz). The high-resolution infrared spectrum, obtained at the Canadian Light Source, allowed for accurate and precise determination of the band origins of its three lowest-energy fundamental modes (ν24, ν17, and ν23). Similar to other cyanoarenes, the first two fundamental modes (ν24,A″, and ν17, A′, for 2-furonitrile) form an a- and b-axis Coriolis-coupled dyad. More than 7000 transitions from each of these fundamental states were fit to an octic A-reduced Hamiltonian (σfit= 48 kHz), and the combined spectroscopic analysis determines fundamental energies of 160.1645522 (26) cm–1and 171.9436561 (25) cm–1for ν24and ν17, respectively. The least-squares fitting of this Coriolis-coupled dyad required 11 coupling terms, Ga, GaJ, GaK, GaJJ, GaKK, Fbc, FbcJ, FbcK, Gb, GbJ, and FacK. Using both the rotational and high-resolution infrared spectra, a preliminary least-squares fit was obtained for ν23, providing its band origin of 456.7912716 (57) cm–1. The transition frequencies and spectroscopic constants provided in this work, when combined with theoretical or experimental nuclear quadrupole coupling constants, will provide the foundation for future radioastronomical searches for 2-furonitrile across the frequency range of currently available radiotelescopes.

Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting enzyme 2 (ACE2)1, could represent a new chemoprophylactic approach for COVID-19 that complements vaccination2,3. However, the mechanisms that control the expression of ACE2 remain unclear. Here we show that the farnesoid X receptor (FXR) is a direct regulator of ACE2transcription in several tissues affected by COVID-19, including the gastrointestinal and respiratory systems. We then use the over-the-counter compound z-guggulsterone and the off-patent drug ursodeoxycholic acid (UDCA) to reduce FXR signalling and downregulate ACE2 in human lung, cholangiocyte and intestinal organoids and in the corresponding tissues in mice and hamsters. We show that the UDCA-mediated downregulation of ACE2 reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ. Furthermore, we reveal that UDCA reduces the expression of ACE2 in the nasal epithelium in humans. Finally, we identify a correlation between UDCA treatment and positive clinical outcomes after SARS-CoV-2 infection using retrospective registry data, and confirm these findings in an independent validation cohort of recipients of liver transplants. In conclusion, we show that FXR has a role in controlling ACE2 expression and provide evidence that modulation of this pathway could be beneficial for reducing SARS-CoV-2 infection, paving the way for future clinical trials.

Using concentration-time data from the NEAT001/ARNS143 study (single sample at week 4 and 24), we determined raltegravir pharmacokinetic parameters using nonlinear mixed effects modelling (NONMEM v.7.3; 602 samples from 349 patients) and investigated the influence of demographics and SNPs (SLC22A6and UGT1A1) on raltegravir pharmacokinetics and pharmacodynamics. Demographics and SNPs did not influence raltegravir pharmacokinetics and no significant pharmacokinetic/pharmacodynamic relationships were observed. At week 96, UGT1A1*28/*28was associated with lower virological failure (p= 0.012), even after adjusting for baseline CD4 count (p= 0.048), but not when adjusted for baseline HIV-1 viral load (p= 0.082) or both (p= 0.089). This is the first study to our knowledge to assess the influence of SNPs on raltegravir pharmacodynamics. The lack of a pharmacokinetic/pharmacodynamic relationship is potentially an artefact of raltegravir’s characteristic high inter and intra-patient variability and also suggesting single time point sampling schedules are inadequate to thoroughly assess the influence of SNPs on raltegravir pharmacokinetics.

In GCSE geography you looked at the huge gap that exists between rich and poor people in LEDC cities such as Rio de Janeiro. You probably remember discussing concepts such […]

A semi-experimental equilibrium structure (reSE) of pyridazine (o-C4H4N2) has been determined using the rotational spectra of 18 isotopologues. Spectroscopic constants of four isotopologues are reported for the first time (measured from 235 to 360 GHz), while spectroscopic constants for previously reported isotopologues are improved by extending the frequency coverage (measured from 130 to 375 GHz). The experimental values of the ground-state rotational constants (A0, B0, and C0) from each isotopologue were converted to determinable constants (A0″, B0″, and C0″), which were then corrected for the effects of vibration–rotation interactions and electron-mass distributions using CCSD(T)/cc-pCVTZ calculations. The resultant reSEfor pyridazine determines bond distances to within 0.001 Å and bond angles within 0.04°, a reduction in the statistical uncertainties by at least a factor of two relative to the previously reported reSE. The improvement in precision appears to be largely due to the use of higher-level theoretical calculations of the vibration–rotation and electron-mass effects, though the incorporation of the newly measured isotopologues ([4-2H, 4-13C]-, [4-2H, 5-13C]-, [4-2H, 6-13C]-, and [4,5-2H, 4-13C]-pyridazine) is partially responsible for the improved determination of the hydrogen-containing bond angles. The computed equilibrium structure (re) (CCSD(T)/cc-pCV5Z) and a “best theoretical estimate” of the equilibrium structure (re) both agree with the updated reSEstructure within the statistical experimental uncertainty (2σ) of each structural parameter.